<p>在谷歌搜索和人工智能答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开谷歌</p>
<p>在谷歌上添加</p>
<p>伦敦 --（商业资讯）--LivaNova PLC（纳斯达克：LIVN），一家市场领先的医疗技术公司，宣布在 6 月 10 日的年度股东大会后，选举 Jette Nygaard-Andersen 为公司董事会成员。</p>
<p>“我们很高兴欢迎 Jette 加入 LivaNova 的董事会，” 主席 William Kozy 说。“她带来了深厚的医疗技术治理专业知识，经过验证的首席执行官领导能力，以及在复杂的全球业务中进行转型、战略并购和数字创新的强大记录。她在国际和上市公司董事会的经验将为 LivaNova 增添宝贵的价值。”</p>
<p>Nygaard-Andersen 是一位拥有超过 25 年领导经验的资深高管和董事会主席，曾在高度监管的国际企业中任职。她目前是丹麦全球医疗器械公司 Coloplast A/S 的董事会主席。自 2015 年以来，她一直担任 Coloplast 的非执行董事，包括担任其薪酬与提名委员会的主席以及审计委员会的成员。</p>
<p>Nygaard-Andersen 在多家全球组织中担任过高级领导职务，拥有跨多个行业和地区的治理、战略和运营执行背景。作为全球体育博彩和游戏公司 Entain plc 的首席执行官和执行董事，她领导了一项全面的业务转型并实现了显著增长。在加入 Entain 之前，Nygaard-Andersen 在纳斯达克北欧上市的欧洲媒体、娱乐和游戏集团 Modern Times Group AB 工作了 16 年，期间历任多个高级执行职位，包括首席运营官和多个业务单元的首席执行官。她拥有哥本哈根大学的工商管理硕士学位，专注于金融。</p>
<p>“LivaNova 拥有坚实的基础和明确的战略前进方向，” Nygaard-Andersen 说。“我期待与董事会和管理团队合作，支持公司在推进创新医疗技术方面的持续增长和影响，这些技术改善了全球患者的生活。”</p>
<p>与 Nygaard-Andersen 的任命同时，Sharon O’Kane 博士在决定不寻求连任后辞去了董事会职务。O’Kane 于 2015 年在 LivaNova 成立后被任命为董事，最近庆祝了她作为董事会成员的十周年。</p>
<p>“我们对 Sharon 在超过十年的杰出和奉献服务中对公司的重要贡献深表感谢，” Kozy 说。“Sharon 在任期内对 LivaNova 产生了持久的影响。她的领导力、洞察力和承诺，特别是在 2017 年担任我们提名与公司治理委员会主席以及 2023-2024 年担任首席独立董事期间，发挥了重要作用，引导公司度过许多关键里程碑。”</p>
<p>Brooke Story 于 2022 年被任命为董事，将接替 O’Kane 担任提名与公司治理委员会的主席，她将与 Nygaard-Andersen、Chris Barry 和 Stacy Enxing Seng 一起工作。Enxing Seng 将结束她作为薪酬与人力资本管理（CHCM）委员会主席的任期，Peter Wilver 将接任该职位，并与 Enxing Seng、Susan Podlogar 和 Francesco Bianchi 一起工作。Todd Schermerhorn 将继续担任审计与合规委员会的主席，Barry、Wilver 和 Don Zurbay 将作为成员。Kozy 将继续担任董事会主席。</p>
<p><strong>关于 LivaNova</strong></p>
<p>LivaNova PLC 是一家全球医疗技术公司，拥有近五十年的经验和改变人们生活轨迹的愿景。通过在特定神经和心脏疾病领域的巧妙医疗解决方案，LivaNova 努力点燃患者的转机。公司总部位于伦敦，拥有约 3300 名员工，并在 100 多个国家开展业务，服务于全球患者、医疗专业人员和医疗系统。有关更多信息，请访问 www.livanova.com。</p>
<p><strong>安全港声明</strong></p>
<p>本新闻稿包含关于公司目标、信念、期望、战略、目标、计划、基本假设和其他不一定基于历史事实的 “前瞻性声明”。这些声明包括但不限于关于董事会的声明。实际事件可能因各种因素而与我们的前瞻性声明中所指示的情况有重大不同，包括公司最近的 10-K 表格年报第 1A 项中列出的因素，以及季度报告 10-Q 表格和当前报告 8-K 表格中包含的任何风险因素。LivaNova 没有义务更新本新闻稿中包含的信息，以反映随后发生的事件或情况。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MTE3OTY2NzByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MTE3OTY2NzByMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260611796670/en/</p>
<p><strong>LivaNova 投资者关系和媒体联系人</strong></p>
<p>+1 281-895-2382</p>
<p><strong>Briana Gotlin</strong></p>
<p>投资者关系副总裁</p>
<p>InvestorRelations@livanova.com</p>
<p><strong>Deanna Wilke</strong></p>
<p>企业传播副总裁</p>
<p>Corporate.Communications@livanova.com</p>
<p>来源：LivaNova PLC</p>

LIVN

<p>LivaNova PLC 宣布在 6 月 10 日的年度股东大会后选举 Jette Nygaard-Andersen 加入其董事会。Nygaard-Andersen 拥有丰富的医疗科技治理和首席执行官领导经验。同时，Sharon O’Kane 博士在服务十年后辞职。公告还详细说明了董事会委员会主席的变更，包括 Brooke Story 接替 O’Kane 担任提名与公司治理委员会主席</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在谷歌搜索和人工智能答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开谷歌</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在谷歌上添加</p>
</div><p>LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the election of Jette Nygaard-Andersen to the Company’s Board of Directors after its Annual General Meeting of shareholders on June 10.</p>
<div class="lb-trans"><p>伦敦 --（商业资讯）--LivaNova PLC（纳斯达克：LIVN），一家市场领先的医疗技术公司，宣布在 6 月 10 日的年度股东大会后，选举 Jette Nygaard-Andersen 为公司董事会成员。</p>
</div><p>“We’re pleased to welcome Jette to LivaNova’s Board,” said William Kozy, Chair. “She brings deep medtech governance expertise, proven CEO leadership, and a strong track record of transformation, strategic M&amp;A, and digital innovation across complex global businesses. Her international and public company board experience will be a valuable addition to LivaNova.”</p>
<div class="lb-trans"><p>“我们很高兴欢迎 Jette 加入 LivaNova 的董事会，” 主席 William Kozy 说。“她带来了深厚的医疗技术治理专业知识，经过验证的首席执行官领导能力，以及在复杂的全球业务中进行转型、战略并购和数字创新的强大记录。她在国际和上市公司董事会的经验将为 LivaNova 增添宝贵的价值。”</p>
</div><p>Nygaard-Andersen is a tenured executive and board chair with more than 25 years of leadership experience in highly regulated international businesses. She is currently Chair of the Board for Coloplast A/S, a global medical device company based in Denmark. She has served as a Non-Executive Director of Coloplast since 2015, including as Chair of its Remuneration and Nomination Committee and as a member of its Audit Committee.</p>
<div class="lb-trans"><p>Nygaard-Andersen 是一位拥有超过 25 年领导经验的资深高管和董事会主席，曾在高度监管的国际企业中任职。她目前是丹麦全球医疗器械公司 Coloplast A/S 的董事会主席。自 2015 年以来，她一直担任 Coloplast 的非执行董事，包括担任其薪酬与提名委员会的主席以及审计委员会的成员。</p>
</div><p>Nygaard-Andersen has held senior leadership roles within multiple global organizations, with a background spanning governance, strategy, and operational execution across a range of industries and geographies. As Chief Executive Officer and Executive Director of Entain plc, a global sports betting and gaming company, she led a comprehensive business transformation and delivered significant growth. Prior to Entain, Nygaard-Andersen spent 16 years at Modern Times Group AB, a Nasdaq Nordic-listed European media, entertainment, and gaming group, where she progressed through a series of senior executive positions including as Chief Operating Officer and, later, as CEO of multiple business units. She holds a Master of Science degree in Business Administration, with a concentration in Finance, from the University of Copenhagen.</p>
<div class="lb-trans"><p>Nygaard-Andersen 在多家全球组织中担任过高级领导职务，拥有跨多个行业和地区的治理、战略和运营执行背景。作为全球体育博彩和游戏公司 Entain plc 的首席执行官和执行董事，她领导了一项全面的业务转型并实现了显著增长。在加入 Entain 之前，Nygaard-Andersen 在纳斯达克北欧上市的欧洲媒体、娱乐和游戏集团 Modern Times Group AB 工作了 16 年，期间历任多个高级执行职位，包括首席运营官和多个业务单元的首席执行官。她拥有哥本哈根大学的工商管理硕士学位，专注于金融。</p>
</div><p>“LivaNova has a strong foundation and a clear strategic path forward,” Nygaard-Andersen said. “I look forward to working with the Board and management team to support the Company’s continued growth and impact as it advances innovative medical technologies that improve the lives of patients worldwide.”</p>
<div class="lb-trans"><p>“LivaNova 拥有坚实的基础和明确的战略前进方向，” Nygaard-Andersen 说。“我期待与董事会和管理团队合作，支持公司在推进创新医疗技术方面的持续增长和影响，这些技术改善了全球患者的生活。”</p>
</div><p>Concurrent with Nygaard-Andersen’s appointment, Dr. Sharon O’Kane stepped down from the Board after deciding not to seek re-election. O’Kane, who was appointed to her position in 2015 following the formation of LivaNova, recently celebrated her 10th anniversary as a Board member.</p>
<div class="lb-trans"><p>与 Nygaard-Andersen 的任命同时，Sharon O’Kane 博士在决定不寻求连任后辞去了董事会职务。O’Kane 于 2015 年在 LivaNova 成立后被任命为董事，最近庆祝了她作为董事会成员的十周年。</p>
</div><p>“We are deeply grateful to Sharon for her many important contributions to the Company during more than a decade of distinguished and dedicated service,” Kozy said. “Sharon has made a lasting impact on LivaNova during her tenure. Her leadership, insight, and commitment, particularly in her role as Chair of our Nominating and Corporate Governance Committee since 2017 and time as Lead Independent Director between 2023-2024, have played an important role in guiding the Company through many key milestones.”</p>
<div class="lb-trans"><p>“我们对 Sharon 在超过十年的杰出和奉献服务中对公司的重要贡献深表感谢，” Kozy 说。“Sharon 在任期内对 LivaNova 产生了持久的影响。她的领导力、洞察力和承诺，特别是在 2017 年担任我们提名与公司治理委员会主席以及 2023-2024 年担任首席独立董事期间，发挥了重要作用，引导公司度过许多关键里程碑。”</p>
</div><p>Brooke Story, who was appointed to the Board in 2022, will succeed O’Kane as Chair of the Nominating and Corporate Governance Committee, where she will serve alongside Nygaard-Andersen, Chris Barry, and Stacy Enxing Seng. Enxing Seng will conclude her tenure as Chair of the Compensation and Human Capital Management (CHCM) Committee, and Peter Wilver will assume that position, where he will be joined by Enxing Seng, Susan Podlogar, and Francesco Bianchi. Todd Schermerhorn will remain Chair of the Audit and Compliance Committee, with Barry, Wilver, and Don Zurbay as members. Kozy will continue to serve as Chair of the Board.</p>
<div class="lb-trans"><p>Brooke Story 于 2022 年被任命为董事，将接替 O’Kane 担任提名与公司治理委员会的主席，她将与 Nygaard-Andersen、Chris Barry 和 Stacy Enxing Seng 一起工作。Enxing Seng 将结束她作为薪酬与人力资本管理（CHCM）委员会主席的任期，Peter Wilver 将接任该职位，并与 Enxing Seng、Susan Podlogar 和 Francesco Bianchi 一起工作。Todd Schermerhorn 将继续担任审计与合规委员会的主席，Barry、Wilver 和 Don Zurbay 将作为成员。Kozy 将继续担任董事会主席。</p>
</div><p><strong>About LivaNova</strong></p>
<div class="lb-trans"><p><strong>关于 LivaNova</strong></p>
</div><p>LivaNova PLC is a global medical technology company built on nearly five decades of experience and a vision to change the trajectory of lives for a new day. Through ingenious medical solutions in select neurological and cardiac conditions, LivaNova strives to ignite patient turnarounds. Headquartered in London, with approximately 3,300 employees and a presence in more than 100 countries, LivaNova serves patients, healthcare professionals, and healthcare systems worldwide. For more information, please visit www.livanova.com.</p>
<div class="lb-trans"><p>LivaNova PLC 是一家全球医疗技术公司，拥有近五十年的经验和改变人们生活轨迹的愿景。通过在特定神经和心脏疾病领域的巧妙医疗解决方案，LivaNova 努力点燃患者的转机。公司总部位于伦敦，拥有约 3300 名员工，并在 100 多个国家开展业务，服务于全球患者、医疗专业人员和医疗系统。有关更多信息，请访问 www.livanova.com。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港声明</strong></p>
</div><p>This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the Board of Directors. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.</p>
<div class="lb-trans"><p>本新闻稿包含关于公司目标、信念、期望、战略、目标、计划、基本假设和其他不一定基于历史事实的 “前瞻性声明”。这些声明包括但不限于关于董事会的声明。实际事件可能因各种因素而与我们的前瞻性声明中所指示的情况有重大不同，包括公司最近的 10-K 表格年报第 1A 项中列出的因素，以及季度报告 10-Q 表格和当前报告 8-K 表格中包含的任何风险因素。LivaNova 没有义务更新本新闻稿中包含的信息，以反映随后发生的事件或情况。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MTE3OTY2NzByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260611796670r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260611796670/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260611796670/en/</p>
</div><p><strong>LivaNova Investor Relations and Media Contacts</strong></p>
<div class="lb-trans"><p><strong>LivaNova 投资者关系和媒体联系人</strong></p>
</div><p>+1 281-895-2382</p>
<div class="lb-trans"><p>+1 281-895-2382</p>
</div><p><strong>Briana Gotlin</strong></p>
<div class="lb-trans"><p><strong>Briana Gotlin</strong></p>
</div><p>VP, Investor Relations</p>
<div class="lb-trans"><p>投资者关系副总裁</p>
</div><p>InvestorRelations@livanova.com</p>
<div class="lb-trans"><p>InvestorRelations@livanova.com</p>
</div><p><strong>Deanna Wilke</strong></p>
<div class="lb-trans"><p><strong>Deanna Wilke</strong></p>
</div><p>VP, Corporate Communications</p>
<div class="lb-trans"><p>企业传播副总裁</p>
</div><p>Corporate.Communications@livanova.com</p>
<div class="lb-trans"><p>Corporate.Communications@livanova.com</p>
</div><p>Source: LivaNova PLC</p>
<div class="lb-trans"><p>来源：LivaNova PLC</p>
</div>

Jette Nygaard-Andersen Joins LivaNova Board as a New Director | LIVN Stock News

Jette Nygaard-Andersen 加入 Livanova 董事会，担任新董事 | LIVN 股票新闻